PharmExec Blog

Is Gender a Drug Safety Issue in the Era of Personalized Medicine?

By Lisa Henderson, Applied Clinical Trials.

In January 2013, FDA told manufacturers to lower the dose of zolpidem, the insomnia treatment, for women, and suggested a 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and Zolpimist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR). That was based on evidence the drug is metabolized more slowly in women, which makes the side effect of next-day impairment more likely in women than men. Read More »

Posted in FDA, Gene therapy, Regulatory, Safety | Tagged , , , , | Leave a comment

Chats Not Charts: Three Steps to Pharma Post-Marketing

by Andrew Spong (originally published on stwem.com)

The air of despondency that is descending over the pharmaceutical industry’s use of social media is perverse.

It has nothing to do with a putative (and also fictive) absence of interest on the patient’s part in connecting with the pharmaceutical industry. It has everything to do with the industry’s anxiety and inability to reorganize itself internally to meet the challenges of interacting with a new audience (patients) in an environment in which it feels exposed and uncomfortable (the social web).

Read More »

Posted in Advertising, E-Media, Guest Blog, leadership, Marketing, Patient Communication, patient education, social media, Strategy | Leave a comment

Celgene’s Abraxane to Lead Boom in Pancreatic Cancer Market

The global pancreatic cancer treatment market value in the six major countries (U.S., France, Germany, Italy, Spain and the UK) will increase  from $529 million in 2012 to $1.63 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 25.2%, says a new report from GlobalData (London, UK).

According to the report, the U.S. will show the most growth in the pancreatic cancer therapeutics market, with its total value jumping from $275 million in 2012 to $1.17 billion by 2017, at a higher CAGR of 33.5%. This will be followed by the five European countries, with their combined market values expected to increase from $254 million in 2012 to $463 million by 2017, (CAGR 12.8%).

Savade Solanki, GlobalData’s Associate Director of Oncology, says that this rapid market expansion is due to the launch of Celgene’s Abraxane in the U.S. and Europe in 2013 and 2014, respectively, along with the incorporation of five pipeline agents into U.S. clinical practice.

Sales of Abraxane are expected to undergo “a massive rise, from $21 million (off-label) in 2012 to $954 million in 2017, at a CAGR of 115%”, says GlobalData. The drug will represent nearly 60% of the pancreatic cancer therapeutics market by the end of the forecast period.

Of the five upcoming pipeline agents, “NewLink Genetics Corporation’s algenpantucel-L is expected to garner the highest sales,” says Solanki. “Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398.”

http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/opportunityanalyzer-pancreatic-canceropportunity-analysis-and-forecasts-to-2017?utm_source=email&utm_medium=pr&utm_campaign=gdhcprq2&utm_nooveride=1

Posted in Gene therapy, Global, healthcare | Tagged , , , | Leave a comment

Closed-Loop Marketing: What Comes Next?

By Morten Hjemlsoe.

One of the questions I’m increasingly being asked at conferences is, “What’s next after CLM?” That’s actually rather nice to hear. To me, the question is like those delightful birds, the swallows, whose appearance announces that spring is on its way: it signifies that we’re ready for things to change. Read More »

Posted in E-Media, Guest Blog, Marketing, multimedia, Technology | Tagged , , , , , | Leave a comment

Pharma Marketers: Avoid the Tactical Scrum

by Al Topin

With the introduction of every new technology, tactic, or gimmick comes what I call a tactical scrum. It’s like watching young kids play their first game of T-ball or soccer. No matter how much instruction the coach gives on field position or game play, the second that ball is hit or kicked, the entire team runs toward it. The result is a scrum of little people all chasing the ball. TopinBlogImage Read More »

Posted in Advertising, Agency Insight, E-Media, Guest Blog, Marketing, People, Sales, social media, Strategy, Technology | Tagged , , , | Leave a comment
  • Categories

  • Meta